Neurological brain disorders Immunoassay kits Ezdiatech's fast and accurate solution for neurological brain disorders

Multiplexed diagnostics of brain diseased(Neurology) | Biomarkers of brain diseases | Clinical Diagnosis The rapid increase of patients with brain diseases, due to rapidly ageing population worldwide, is expected to incur two trillion USD medical care costs from 75 million patients by 2030. As population ageing in Korea is progressing 4.5times faster than that of other OECD countries, it is evident that brain diseases such as dementia, Alzheimer's, and cerebral infarction will become a more serious social issue. Traditionally, for diagnosis of dementia, Alzheimer's and other brain diseases, combined...

Multiplexed diagnostic technology Multiplexed diagnostic technology VEUS is a fully automated ALL-IN-ONE diagnostic system for rapid and accurate immunoassays and molecular diagnostics. 1. Rod Shaped Magnetic Particles (RSMP) The ingenious magnetic particle with outstanding performance and reproducibility. RSMP structure Multiple 'functional groups' can be applied Multi-diagnosis principle of RSMP RSMP has superior strengths in all aspects such as productivity, reproducibility, precision, availability and cost compared to conventional magnetic particles. 2. Magnetic Particles Moving Reaction...

GFAP & UCH-L1 VEUPLEX™ TBI assay (GFAP, UCH-L1) (for IVD) · The combination of GFAP and UCH-L1 biomarkers gives a more precise result in determining the severity of head injuries. GFAP indicates glial cell damage, while UCH-L1 indicates neuronal damage. Thus, both proteins provide a more comprehensive evaluation by reflecting damage from different cell types. · Especially in the case of mild traumatic brain injuries (e.g. after sports injuries or traffic accidents), the use of these biomarkers is often used to assess the severity of the trauma and to reduce unnecessary imaging tests (e.g. CT...

GFAP VEUPLEX™ Neuro 1p-B (GFAP) (for RUO) · GFAP is one of the main structural proteins of astrocytes in the central nervous system. In Parkinson's disease, GFAP levels may increase due to damage to glial cells in the brain and the inflammatory process (astrogliosis). · In Multiple Sclerosis (MS), activation and damage to glial cells, including astrocytes, leads to inflammation and scar tissue (sclerosis) in the brain and spinal cord tissue. An increase in GFAP levels indicates glial cell damage, and this wound healing process is known as astrogliosis. · And GFAP may be useful in differentiating...

| Background • NfL is a structural part of the axons of nerve cells. When axons are damaged or broken down, NfL is released into the blood and cerebrospinal fluid. In Parkinson's disease, axonal degeneration is an important pathological process. NfL reflects the degree of neuronal damage and can be used to monitor the progression of Parkinson's disease. • NfL can also be used to distinguish Parkinson's disease from other neurodegenerative diseases such as atypical parkinsonism (e.g. Multiple System Atrophy or Progressive Supranuclear Palsy). • NfL levels are usually higher in these diseases,...

pTau 181, pTau 231, Total Tau • Tau protein is a protein that stabilizes the internal structure of nerve cells. In Alzheimer's disease, the tau protein is abnormally phosphorylated and accumulates within nerve cells. This accumulation leads to neuron death, impairing brain functions. ■ Total Tau reflects neuron damage and degeneration in the brain. In people with Alzheimer's disease, total tau levels in the CSF increase, indicating damage to nerve cells. High levels of total tau are common in the advanced stages of Alzheimer's. ■ p-Tau (Phosphorylated Tau) indicates abnormal phosphorylation (addition...

Amyloid p 40, Amyloid p 42 VEUPLEX™ Neuro 2p-B (Amyloid p 40, 42) (for RUO) | Background • Amyloid beta (Ap) is a protein that plays a major role in Alzheimer's disease. Amyloid beta proteins accumulate in the brain, forming amyloid plaques and disrupting communication between nerve cells. These plaques are one of the main components of Alzheimer's pathology. • Ap 42 is the most important form in Alzheimer's disease. Ap 42 is a longer protein fragment than Ap 40 and tends to accumulate within plaques. In Alzheimer's patients, Ap 42 levels in the CSF decrease while the protein accumulates in the...

| Background ■ Alpha-synuclein is a protein found in nerve cells. In Parkinson’s disease, this protein folds abnormally, forming pathological aggregation known as Lewy bodies. This aggregation is an important biological feature of Parkinson’s disease. ■ Pathological accumulation of alpha-synuclein causes damage to dopamine-producing neurons, which leads to motor and cognitive symptoms typical of Parkinson’s disease. ■ Alpha-synuclein biomarkers can be helpful in diagnosing Parkinson's disease. Total alpha-synuclein levels in cerebrospinal fluid (CSF) are usually low in Parkinson’s patients because...

VEUDx Analyzer MFDS Medical Device approved CE IVDR approved VEUDx Analyzer · Principle : Fluorescence coding/analysis · Size : 530 mm(L) X 485 mm(D) X 465 mm(H) · Weight : 33.8 kg · Cartridge slots: up to 6 cartridges Desorption Tray type · Power Supply : AC 100-120V, 50/60Hz or AC 200-240V, 50/60Hz · Display : 7 inch Touch LCD, 1024 X 600 VEUS (Versatile, Easy, and User-friendly IVD System) is an innovative diagnostic system: Versatile – almost all in vitro diagnostic items are applicable; Easy – the system is entirely automated enabling easy testing with no pretreatment required; User-friendly...

Business application field Business application field Pharmaceutical companies Research institutes Product Name VEUDx analyzer Spin down Centrifuge with Rotor VEUPLEX™ Neuro 1p-B (GFAP) VEUPLEX™ Neuro 2p-A (GFAP, UCH-L1) VEUPLEX™ Neuro 3p-A(pTau 181, pTau 231, Total Tau) VEUPLEX™ Neuro 1p-G (Amyloid β 40) VEUPLEX™ Neuro 1p-H (Amyloid β 42) VEUPLEX™ Neuro 1p-I (α-synuclein) Quality Control VEUPLEX™ Neuro 2p-A (GFAP, UCH-L1) QC VEUPLEX™ Neuro 2p-A (GFAP, UCH-L1) Calibrator